April 15, 2020 09:58 AM EDT
FDA+
Coronavirus

FDA of­fers guid­ance for gener­ic drug de­vel­op­ers of hy­drox­y­chloro­quine, chloro­quine

Zachary Brennan

Senior Editor

The FDA on Mon­day is­sued two new prod­uct-spe­cif­ic guid­ance doc­u­ments for the un­proven but high­ly de­mand­ed po­ten­tial Covid-19 drugs chloro­quine phos­phate and hy­drox­y­chloro­quine sul­fate. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times